You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: Vaccine production is not a problem for India, cold chain is

As India prepares a road map for a Covid-19 vaccination drive next year, the lack of cold chain infrastructure is a key bottleneck

Topics
Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Sohini Das  |  Mumbai 

Coronavirus, vaccine, covid, drugs, clinical trials

India is likely to start vaccination drive around January 2021 and is now preparing the road map for what will be perhaps the world's largest vaccination drive next year. Data shows that India has ample manufacturing capacity (about 2.5 bn doses) that would be sufficient to meet both domestic and export demand, however, analysts point out that cold chain infrastructure is a key bottleneck.

According to Credit Suisse analysts India would need about 1.7 bn Covid-19 vaccine doses to vaccinate a majority of its adult population. The target is to administer 500 mn doses (or 250 mn people) by July next year. The key vaccines the country is banking on are from AstraZeneca, Novavax and Bharat Biotech and the earliest efficacy data is not expected before November-December 2020.

As for the cold chain infrastructure, India's current immunisation programme handles around 600 mn doses and the private sector has a capacity of about 250-300 mn doses. With this, the potential vaccinations reach 550-600 mn doses annually, claims Credit Suisse. Add to this manpower required to give the jab would be around 100,000 people. Mass inoculation of India's population is likely to be achieved only by end of 2023, analysts feel.

The government has already started preparing database of priority beneficiaries and has issued advisory at district and state levels to prepare database and upload to Covid-19 Vaccine Beneficiary Management System. The database of healthcare workers is expected to be ready soon, database of people above 50-years and frontline workers is ready. Challenge is in preparing the database of people with co-morbidities where data is currently limited to screening of people at 48,000 health centers.

Syringe and vial makers are already in ramp up mode and India is unlikely to face any supply constraint at least in the first half of 2021. In the cold chain, analysts feel the storage is not the issue, but transportation is. The organised sector does not have reach into the hinterlands and the government is likely to use existing fruit and vegetable cold storage and the Universal Immunisation Program network to serve these areas.

India needs 1.7 bn doses for its population
Total Population (mn) 1380
Population above 14 yrs 80%
Population with antibodies by March 2021 (estimates) 25%
Number of Indians to be vaccinated (mn) 828
Dose per person 2
Total Doses (mn) 1656


Priority groups identified for first phase of CoViD-19 vaccination in India
Priority Population Segment No. of Beneficiaries (mn)
Healthcare Workers 7
MBBS doctors 1.1
Nurses 1.5
Frontline workers 21
Municipal workers, public transport drivers etc 15
Police and Armed forces 6
People above 50 yrs 260
People less than 50 yrs but with co-morbidities (estimates) 12
Total 300


Vaccine production and Clinical Trial timelines
Players with candidates Capacity (mn doses) Clinical Trial update Temperature Requirements
Serum - AstraZeneca 1000 Phase 3 by December 2020 2-8 degree celsius
Serum - Novavax 500 Phase 2/3 to start by Dec 2020 2-8 degree celsius
Cadila - DNA vaccine 100 Phase 3 by March 2021 2-8 degree celsius
Aurobindo- Viral vector facility 300
Russian vaccine 100 Phase 2/3 India trials to end by March 2021 2-8 degree celsius ***
Biological E-J&J ** 400 J&J global data expected in Q1CY21 2-8 degree celsius
Bharat Biotech * 150 Phase 3 started in October 2-8 degree celsius
Total (estimates) 2550

* Bharat Biotech is trying to take capacity up to 500 mn doses/yr

** Biological E has capacity to make 1 bn doses for Texas based Baylor College of Medicine (BCM)'s recombinant protein vaccine candidate

*** one variant may need -20 degree celsius

Key domestic logistics players offering cold chain storage and transportation across the country
Company Capacity Remarks
Snowman Logistics 1 lakh pallets, 289 vehicles, 33 warehouses Largest organized player, can ramp up storage capacity to 650mn doses if it can repurpose all the food storage warehouses
Gati Kausar 5500 pallets, 160 vehicles Primary/Secondary distribution, dedicated reefer fleet, customized cold chain solutions for multiple industries, including healthcare
Future Supply Chain Solutions 8400 Pallets, 4 Distribution Centers Storage temperature ranges from -25°C to +25°C
Transport Corporation of India 7000 pallets Stores and transports agricultural products, processed foods, FMCG, healthcare products, etc
Mahindra Logistics NA State-of-the-art temperature controlled warehouse for pharmaceuticals opened recently


Current Cold Storage - electric and non-electric - in use in India
ELECTRIC
Equipment Temperature (degree celsius)
Cold Rooms 2 to 8
Walk in cooler 2 to 8
Walk in Freezers -15 to -25
Ice Lined Refrigerators 2 to 8
Deep Freezer -15 to -25
NON-ELECTRIC
Cold Box 2 to 8
Vaccine carrier 2 to 8

Source: Company Updates, Credit Suisse

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 16 2020. 10:37 IST
RECOMMENDED FOR YOU